Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Courtney

Showing results (511-520 of 539) with videos related to

Pageof 54
Sort By:
Hepato-Gastroenterology|August 3, 1999
Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate reportF N Gilly, A Beaujard, J Bienvenu, et al.
Biomaterials|June 22, 2005
Assessing the in vitro biocompatibility of a novel carbon device for the treatment of sepsisSusan R Sandeman, Carol A Howell, Gary J Phillips, et al.
Biomaterials|June 30, 2006
The in vitro adsorption of cytokines by polymer-pyrolysed carbonCarol A Howell, Susan R Sandeman, Gary J Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitorsStephen M Courtney, Philip A Hay, Richard T Buck, et al.
The Journal of Arthroplasty|October 24, 2018
Hip and Knee Section, Treatment, Algorithm: Proceedings of International Consensus on Orthopedic InfectionsThanainit Chotanaphuti, Paul M Courtney, Brianna Fram, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
Nature Structural & Molecular Biology|March 29, 2016
Solid-state NMR structure of a pathogenic fibril of full-length human α-synucleinMarcus D Tuttle, Gemma Comellas, Andrew J Nieuwkoop, et al.
Gynecologic Oncology|January 15, 2023
The role of adjuvant treatment for early-stage uterine clear cell carcinomasT J Orellana, A A Garrett, T R Soong, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitorStephen M Courtney, Philip A Hay, Richard T Buck, et al.
Pageof 54

Showing results (511-520 of 539) with videos related to

Sort By:
Pageof 54
Hepato-Gastroenterology|August 3, 1999
Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate reportF N Gilly, A Beaujard, J Bienvenu, et al.
Biomaterials|June 22, 2005
Assessing the in vitro biocompatibility of a novel carbon device for the treatment of sepsisSusan R Sandeman, Carol A Howell, Gary J Phillips, et al.
Biomaterials|June 30, 2006
The in vitro adsorption of cytokines by polymer-pyrolysed carbonCarol A Howell, Susan R Sandeman, Gary J Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitorsStephen M Courtney, Philip A Hay, Richard T Buck, et al.
The Journal of Arthroplasty|October 24, 2018
Hip and Knee Section, Treatment, Algorithm: Proceedings of International Consensus on Orthopedic InfectionsThanainit Chotanaphuti, Paul M Courtney, Brianna Fram, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
Nature Structural & Molecular Biology|March 29, 2016
Solid-state NMR structure of a pathogenic fibril of full-length human α-synucleinMarcus D Tuttle, Gemma Comellas, Andrew J Nieuwkoop, et al.
Gynecologic Oncology|January 15, 2023
The role of adjuvant treatment for early-stage uterine clear cell carcinomasT J Orellana, A A Garrett, T R Soong, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitorStephen M Courtney, Philip A Hay, Richard T Buck, et al.
Pageof 54